Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IBM Watson Health

- PMLiVE

Chiesi targets patient adherence via mobile app

Initiative will see asthma and COPD patients receive device training support

- PMLiVE

New trial results suggest CAR-T effects are durable in lymphoma

Novartis and Celgene/Juno release longer term data on important lymphoma indication at EHA

- PMLiVE

Drugs for rare diseases will help propel pharma sales to $1.2trn by 2024; report

Orphan drug sales growth will be 11%+ a year

- PMLiVE

Aptar Pharma advances digital offerings

Partners up with digital therapeutics company Propeller Health

- PMLiVE

Rosalind Franklin Institute invests £6m in disruptive technologies

Will open new AI-enabled research facility based in the UK

- PMLiVE

Novartis bribery probe in Greece ‘could affect general election’

The pharma giant allegedly gave “bundles of cash” to civil servants, doctors and politicians

- PMLiVE

ICER says price of Amgen/Novartis’ Aimovig is OK – if used last-line

Recommends the drug should only be used in patients who have exhausted other prevention options

Novartis changes executive committee

Robert Welteverden is appointed head of Novartis Business Services

Global mHealth market predicted to reach $58.8bn by 2020

And digital therapeutics could rival mainstream pharmaceutical products, according to a report

- PMLiVE

Real-world data finds patients feel better on Entresto, says Novartis

Patients on Entresto reported an “early, statistically significant improvement in health status”

- PMLiVE

Novartis, Amgen set low price for first CGRP migraine drug

Aimovig has a list price of $6,900 per year

- PMLiVE

Novartis legal head resigns over Cohen payments

General counsel steps down, but Novartis still facing difficult questions

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links